Abstracts tagged "Biologic agents"

Abstract Number: 1369 • 2019 ACR/ARP Annual Meeting
Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy
Ji-Won Kim¹, Jin-Sun Kong ², Youngjae Park ³ and Wan-Uk Kim ³, ¹Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, ²Catholic University of Korea, College of Medicine, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Previously, we demonstrated the direct pro-inflammatory role of the vascular endothelial growth factor (VEGF) and the placenta growth factor (PlGF), and angiogenic factors in…
Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Xue Han¹, Joshua Bryson ¹, David C Crosby ¹, Michael Evans ² and Gabriela Schmajuk ³, ¹Bristol-Myers Squibb, Princeton, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
Abstract Number: 1437 • 2019 ACR/ARP Annual Meeting
Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁴, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of complication in patients with rheumatoid arthritis (RA) and its presence often has an effect on the management…
Abstract Number: 1496 • 2019 ACR/ARP Annual Meeting
Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study
Josef Smolen¹, Panagiotis Athanassiou ², Paul Bergmans ³, Irina Bondareva ⁴, Kurt De Vlam ⁵, Elisa Gremese ⁶, Beatriz Joven-Ibáñez ⁷, Tatiana Korotaeva ⁸, Wim Noël ⁹, Michael Nurmohamed ¹⁰, Petros Sfikakis ¹¹, Stefan Siebert ¹², Pavel Smirnov ¹³, Elke Theander ¹⁴ and Laure Gossec ¹⁵, ¹Medical University of Vienna, Vienna, Austria, ²General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ³Biostatistics and Medical Affairs, Janssen, Tilburg, Netherlands, ⁴GUZ Kemerovo Regional Clinical Hospital, Kemerovo, Russia, ⁵University Hospitals Leuven, Leuven, Belgium, ⁶Fondazione Policlinico Gemelli-Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁹Biostatistics and Medical Affairs, Janssen, Brussels, Belgium, ¹⁰Reade and VU Rheumatology Research Department, Amsterdam, Netherlands, ¹¹Joint Rheumatology Programme, National & Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ¹³Biostatistics and Medical Affairs, Janssen, Moscow, Russia, ¹⁴Biostatistics and Medical Affairs, Janssen, Solna, Sweden, ¹⁵Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Among the treatment options for PsA, IL-12/23 inhibition with ustekinumab (UST) was the first new biologic mode of action after TNF inhibitors (TNFi). Few…
Abstract Number: 1500 • 2019 ACR/ARP Annual Meeting
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Fernando Pimentel-Santos ¹, Nélia Gouveia ³, Anabela Barcelos ⁴, Jaime Branco ¹, Miguel Bernardes ⁵, Raquel Miriam-Ferreira ⁵, Elsa Vieira-Sousa ⁶, Sofia Barreira ⁶, Filipe Vinagre ⁷, Raquel Roque ⁷, Helena Santos ⁸, Nathalie Madeira ⁸, João Rovisco ⁹, Alexandra Daniel ⁹ and Sofia Ramiro ¹⁰, ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³CEDOC, NOVA-Medical School, Lisbon, Portugal, Lisboa, Portugal, ⁴Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ⁵Rheumatology, Centro Hospitalar de São João, Porto, Portugal, Porto, Portugal, ⁶Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ⁷Rheumatology, Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, ⁸Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ⁹Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal, ¹⁰Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands
Background/Purpose: Over the last years, and mostly due to lack of alternatives, it has been common practice to start a second TNF inhibitor (TNFi) in…
Abstract Number: 573 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis
Pascal Hilliquin¹, Thomas Barnetche², Guy Baudens³, Ralph Niarra⁴, Isabelle Idier⁵ and Alain Saraux⁶, ¹Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHR Valenciennes, Valenciennes, France, ⁴Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, ⁵Medical department, Chugai Pharma France, Paris La Defense, France, ⁶Rheumatology, CHU Brest, Brest, France
Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital…
Abstract Number: 1615 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Moa Lee¹, Rishi J. Desai², Yinzhu Jin³, Gregory Brill¹, Alexis Ogdie⁴ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease is a major comorbidity in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Increasing evidence suggests a potential reduction in the risk…
Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
Dongze Wu¹, Tingting Xu², Isaac T. Cheng¹, Steven H.M. Lam¹, Jiang Yue¹, Priscilla Wong¹, Edmund Li¹, Tena K. Li¹ and Lai-Shan Tam³, ¹Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, ²China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong
Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…
Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Ted R. Mikuls¹, Amrita Bath², Bryant R. England³, Michael J. Duryee⁴, Carlos D. Hunter⁴, Joel Kremer⁵, Dimitrios A. Pappas^6,7, William H. Robinson⁸, Jeffrey R. Curtis⁹ and Geoffrey M. Thiele¹⁰, ¹Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Albany Medical Center, Albany, NY, ⁶Columbia University, New York, NY, ⁷Corrona, LLC, Waltham, MA, ⁸Stanford University, Palo Alto, CA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…
Abstract Number: 1655 • 2018 ACR/ARHP Annual Meeting
Achieving Remission in Psoriatic Arthritis By Early Initiation of TNF Inhibition: A Double-Blind, Randomized, Placebo-Controlled Trial of Golimumab + Methotrexate Versus Placebo + Methotrexate
Leonieke van Mens¹, Jet de Jong², Inka Fluri¹, Marleen van de Sande³, Michael Nurmohamed⁴, M.R. Kok⁵, Arno van Kuijk⁶ and Dominique Baeten², ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands
Background/Purpose: In inflammatory arthritis such as RA, early initiation of highly effective targeted treatments is a successful strategy to aim for sustained remission.1 Here we…
Abstract Number: 2676 • 2018 ACR/ARHP Annual Meeting
SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
Ioannis Parodis^1,2, Sharzad Emamikia^1,2, Alvaro Gomez¹ and Katerina Chatzidionysiou^2,3, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In systemic lupus erythematosus (SLE), organ damage is associated with unfavourable disease courses and premature mortality. We aimed at investigating the impact of organ…
Abstract Number: 590 • 2018 ACR/ARHP Annual Meeting
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
Patricia Bogas¹, Chamaida Plasencia², Victoria Navarro-Compán³, Diego Benavent², Gabriela Gonzalez², María Gema Bonilla Hernán², Irene Monjo¹ and Juan Molina¹, ¹Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: In the last two decades the treatment in patients with rheumatoid arthritis (RA) has undergone major advances, especially due to the appearance of new…
Abstract Number: 1704 • 2018 ACR/ARHP Annual Meeting
Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Ioannis Parodis^1,2, Sharzad Emamikia^1,2, Iva Gunnarsson^1,2, Ronald F. van Vollenhoven^2,3 and Katerina Chatzidionysiou^1,4, ¹Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Amsterdam Rheumatology and Immunology Center ARC, Department of Clinical Immunology & Rheumatology, University of Amsterdam, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Drug development in systemic lupus erythematosus (SLE) has been challenging. One of the reasons can be traced in the choice of outcome measures. In…
Abstract Number: 2823 • 2018 ACR/ARHP Annual Meeting
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
Daniela Santos Faria¹, Mónica Eusébio², Joana Leite Silva³, Joana Ramos Rodrigues¹, Joana Sousa Neves¹, Ana Catarina Duarte⁴, Carina Lopes⁵, Ana Valido⁶, Joana Dinis⁶, João Freitas⁷, Mariana Santiago⁷, Raquel Ferreira⁸, Sara Ganhão⁹, Luís Cunha Miranda¹⁰, Daniela Peixoto¹, Filipa Teixeira¹, Sérgio Alcino¹, Carmo Afonso¹, José Tavares Costa³ and Maria José Santos¹¹, ¹Rheumatology, ULSAM, Ponte de Lima, Portugal, ²Sociedade Portuguesa de Reumatologia, Lisboa, Portugal, LIsboa, Portugal, ³Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ⁴Rheumatology, Hospital Garcia de Orta, Almada, Portugal, ⁵Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ⁶Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, ⁷Rheumatology, Centro Hospitalar e Universitário de Coimbra, CHUC-EPE, Coimbra, Portugal, ⁸Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ⁹Rheumatology, Centro Hospitalar de São João, Porto, Portugal, ¹⁰Instituto Português de Reumatologia, Lisbon, Portugal, ¹¹Reuma.pt, Almada, Portugal, Almada, Portugal
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are highly effective treatments for active Rheumatoid Arthritis (RA). However, up to 40% of patients either fail to respond…
Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…